GLS抗体;GLS Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell lysate, Primary antibody: P11792(GLS Antibody) at dilution 1/850, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11792(GLS Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P11792(GLS Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

Glutaminase (GLS) antibodies are essential tools for studying the role of glutaminase enzymes, which catalyze the hydrolysis of glutamine to glutamate—a critical step in cellular metabolism. Glutaminase exists as two primary isoforms: GLS1 (kidney-type) and GLS2 (liver-type). GLS1 is ubiquitously expressed and plays a key role in cancer cell metabolism by supporting the tricarboxylic acid (TCA) cycle and nucleotide biosynthesis, making it a focal point in oncology research. GLS2. though less characterized, is implicated in antioxidant defense and is often downregulated in certain cancers but upregulated in others, such as hepatocellular carcinoma.

GLS antibodies are widely used in immunoblotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and regulation in both physiological and pathological contexts. Their application spans cancer research, neurodegenerative diseases (e.g., Alzheimer’s), and metabolic disorders, where dysregulated glutaminolysis is observed. Notably, GLS1 inhibitors are under clinical investigation as anticancer agents, driving demand for reliable antibodies to validate target engagement and therapeutic efficacy. However, challenges remain in isoform specificity, as cross-reactivity between GLS1 splice variants (e.g., KGA vs. GAC) or GLS2 can complicate data interpretation. Recent advances in antibody validation techniques, including CRISPR-based knockout controls, have improved reliability. These reagents continue to support discoveries linking glutamine metabolism to cell proliferation, redox homeostasis, and disease progression.